Core Viewpoint - Zhongji Changshou Science (00767) plans to acquire 25% of the issued share capital of Comprehensive Cell Bank Limited from China International Orthopedic Medical Group Co., Ltd. for an initial consideration of HKD 300 million, with the possibility of issuing redeemable convertible bonds up to HKD 300 million to finance this acquisition [1] Group 1: Acquisition Details - The acquisition is set to take place on December 1, 2025, with an initial payment of HKD 300 million [1] - The company will issue redeemable convertible bonds to cover the initial consideration, with a maximum amount of HKD 300 million [1] Group 2: Target Company Operations - The target company operates a boutique high-end customized stem cell and IPSC storage center, providing testing and preclinical immunotherapy services to clients, particularly high-net-worth individuals in Hong Kong and mainland China [1] - The target company operates under the trade names of Weisman Academician International Advanced Medical Center and Asia International Medical Testing Center, staffed by registered doctors and laboratory technicians [1] Group 3: Market Potential - The board believes that stem cell and IPSC storage services, along with cellular immunotherapy medical services, represent a new business area with significant growth potential [1] - Cellular immunotherapy services are experiencing exponential growth, driven by increased consumer demand and investment interest in advanced skin regeneration, comprehensive vitality enhancement, holistic health management, and proactive health management strategies [1]
中基长寿科学(00767)拟3亿港元收购亚洲综合细胞库有限公司25%股权